読み込み中
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
前日終値
$62.205
−$0.835 · -1.32%
市場前
$63.8411
+$1.6361 · +2.63%
10月9日 4:26 ET
日中の時刻はETです。市場データは遅延する場合があります。
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
日中レンジ
現在 $62.205
52週レンジ
現在 $62.205
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
8
著しい割高
センチメント
57
まちまち
リスク
56
やや高いリスク
モメンタム
70
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
日中レンジ
現在 $62.205
52週レンジ
現在 $62.205
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3.8億 USD | 3.34億 USD | 2.8億 USD | 3.22億 USD | 2.96億 USD |
| 売上原価 | 1.23億 USD | 1.1億 USD | 1.02億 USD | 1.12億 USD | 9738.9万 USD |
| 粗利益 | 2.57億 USD | 2.24億 USD | 1.78億 USD | 2.1億 USD | 1.99億 USD |
| 研究開発 | 7142.9万 USD | 7240.5万 USD | 8186.6万 USD | 9038.8万 USD | 7652.5万 USD |
| 販売・一般管理 | 2.1億 USD | 2.06億 USD | 2.01億 USD | 1.96億 USD | 1.52億 USD |
| 営業費用 | 2.82億 USD | 1.83億 USD | 3.82億 USD | 2.87億 USD | 2.29億 USD |
| 受取利息 | 917.4万 USD | 1176.5万 USD | 1186.7万 USD | 376.2万 USD | 16万 USD |
| 減価償却費と償却費 | 2041.6万 USD | 1975.7万 USD | 1982.4万 USD | 1600.7万 USD | 1188.5万 USD |
| 営業利益 | −2507.1万 USD | 4076.5万 USD | −2.03億 USD | −7723.1万 USD | −2972.6万 USD |
| 純利益 | −2135.4万 USD | 5254.9万 USD | −1.9億 USD | −7661.3万 USD | −3066.2万 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$62.25
上昇余地（0.07%）この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P Biotech ETFXBI8560.64万0.85%101.08億 USD0.35%$149.29-0.63%
iShares Russell 2000 ETFIWM8500.45万0.11%776.97億 USD0.19%$277.57-0.05%
ARK Genomic Revolution ETFARKG8487.26万4.14%15.57億 USD0.75%$49.29-1.70%
Vanguard Morningstar Total Stock Market ETFVTI7798.97万0.00%2.3兆 USD0.03%$379.56-0.39%
iShares Russell 2000 Growth ETFIWO3024.78万0.22%140.44億 USD0.24%$353.47-0.53%
Vanguard Extended Market ETFVXF3009.54万0.03%954億 USD0.05%$233.13-0.15%
Dimensional - US Small Cap ETFDFAS2515.76万0.07%336.6億 USD0.31%$78.10+0.23%
iShares Biotechnology ETFIBB2256.41万0.22%104.14億 USD0.44%$200.48-1.41%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
